WEBULL
WebtradeDownload

Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following Pipeline Update

Simply Wall St · 20h ago
  • CRISPR Therapeutics reported third quarter 2026 revenue of US$12.67 million and a net loss of US$111.44 million, alongside continued Casgevy uptake and expanding approvals. The company also appointed experienced manufacturing leader Sivakesava Sakhamuri as Chief Technical Officer on November 2, 2026.
  • The combination of rising collaboration revenue, a broader late stage gene editing pipeline and new zugo cel data heading to a major hematology meeting highlights how CRISPR Therapeutics is working to balance commercial traction with substantial ongoing R&D and manufacturing build out costs.
  • We will look at how CRISPR Therapeutics' investment narrative is shaped by Casgevy momentum alongside expanding gene editing pipeline commitments.

Compare CRISPR Therapeutics' gene editing story with other high potential healthcare AI and biotech plays by reviewing the hand picked 38 healthcare AI stocks that are already attracting attention.

What Is CRISPR Therapeutics' Investment Narrative?

To own CRISPR Therapeutics, you need to believe that a high cost, high complexity gene editing platform can turn early products like Casgevy and assets such as zugo cel into a sustainable business, despite years of losses. The latest quarter reinforces that trade off. Revenue of US$12.67 million is still small, while the firm reported a net loss of US$111.44 million and continues to spend heavily on development and manufacturing capacity. Casgevy uptake and upcoming data at ASH keep the near term catalyst picture focused on clinical and commercial execution rather than financial metrics.

The appointment of Siva Sakhamuri as Chief Technical Officer fits that reality. CRISPR Therapeutics is clearly gearing its operations for larger scale cell and gene therapy manufacturing, which is capital intensive and operationally demanding. Investors are being asked to accept a business that is expected to remain unprofitable over the next 3 years, with execution on Casgevy, zugo cel and the broader pipeline doing most of the work in the story while the share price has drifted over the past year.

That said, there is one uncomfortable thread running through CRISPR Therapeutics’ story that rarely shows up in the headlines and it relates to ...

There's only one way to know the right time to buy, sell or hold CRISPR Therapeutics. Head to Simply Wall St's company report for the latest analysis of CRISPR Therapeutics's Fair Value.

NasdaqGM:CRSP 1-Year Stock Price Chart
NasdaqGM:CRSP 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate take on CRISPR Therapeutics focuses on pipeline risk rather than Casgevy momentum. The most pessimistic analysts were modeling only about US$47.3 million of revenue and US$7.6 million of earnings by 2029 before this quarter, a much leaner outlook. Use that spread in expectations as a reminder to weigh several competing stories yourself.

Explore 2 other CRISPR Therapeutics fair value estimates, including one that suggests it could be worth just $74.33!

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond CRISPR Therapeutics?

Once you have a handle on CRISPR Therapeutics, it can help to widen the lens and compare it with other opportunities that fit different risk and return profiles. The Simply Wall St Screener gives you an easy way to scan for stocks with traits that match what you care about most, whether that is value, resilience, income or long term quality.